Business Context and Reporting Period
This Form 8-K Current Report from Anteris Technologies Global Corp. (AVR) covers events occurring on September 29, 2025. The filing details the results of a Special Meeting of stockholders and provides a material update regarding the timeline of the Company's global pivotal registration trial, the PARADIGM Trial.
Key Financial Metrics
This filing is a current report regarding corporate governance and operational updates. It does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the Company's most recent 10-K or 10-Q for financial data.
Material Changes and Voting Results
A Special Meeting was held on September 29, 2025, with 18,687,740 shares present (approximately 51.8% of outstanding shares). Two proposals were approved:
- Proposal 1 (ASX Waiver Proposal): Stockholders approved a waiver from Australian Securities Exchange Listing Rule 7.1, permitting the issuance of new securities without further stockholder approval under that rule.
- Votes For: 13,655,466
- Votes Against: 2,601,191
- Abstentions: 2,431,083
- Proposal 2 (Adjournment Proposal): Stockholders approved the ability to adjourn the meeting to solicit additional proxies if necessary. No adjournment was required as Proposal 1 passed.
- Votes For: 13,762,610
- Votes Against: 2,461,912
- Abstentions: 2,463,218
Outlook, Management Commentary, and Risks
PARADIGM Trial Update:
- Timeline Change: Patient enrollment in the global pivotal registration trial, initially expected in the third quarter of 2025, is now anticipated to commence in the fourth quarter of 2025.
- Regulatory Status: The delay follows a request from the U.S. Food and Drug Administration (FDA) for additional information, primarily regarding bench testing, during the Investigational Device Exemption (IDE) review.
- Resolution: The Company has submitted a formal response addressing the FDA's requests. The IDE submission includes the clinical study protocol and technology package for the DurAVR THV System.
- Global Progress: Regulatory submissions to competent authorities in Europe are currently underway.
Key Facts for Investor Verification
- Verify the specific terms of the ASX Listing Rule 7.1 waiver approved by stockholders to understand future capital raising flexibility.
- Confirm the revised Q4 2025 start date for the PARADIGM Trial enrollment against previous guidance.
- Monitor the FDA's response to the Company's formal submission regarding bench testing to assess the risk of further delays.
- Review the status of European regulatory submissions mentioned in the filing.